Luke Halpern

Eli Lilly's investigational triple hormone receptor agonist achieved average weight loss of up to 70.3 pounds over 80 weeks.

Community pharmacists emerged as the critical clinical link in the modern patient care continuum

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.

On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.

If approved for this indication, finerenone would become the first nonsteroidal mineralocorticoid receptor antagonist indicated for adults with type 1 diabetes and CKD.

Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

A cross-sectional analysis of nearly 30,000 US adults found that economic instability, food insecurity, limited education, and poor social context each independently elevated the odds of advanced cardiovascular-kidney-metabolic (CKD) syndrome—but not equally across all groups.